Insmed (INSM) Income towards Parent Company (2010 - 2026)
Insmed (INSM) recorded quarterly Income towards Parent Company of -$163.6 million in Q1 2026, up 50.21% quarter-over-quarter from -$328.5 million in Q4 2025, and up 36.25% on a YoY basis from -$120.0 million in Q1 2025.
Insmed (INSM) Income towards Parent Company (2010 - 2026) Analysis & Trends
Insmed's Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$163.6 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 36.25% year-over-year to -$163.6 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 16.82% YoY), while the FY2025 annual figure was -$1.3 billion, down 39.73% from the prior year.
- Income towards Parent Company was -$163.6 million for Q1 2026 at Insmed, up from -$328.5 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$94.6 million in Q1 2022 to a low of -$370.0 million in Q3 2025.
- Historically, Income towards Parent Company has averaged -$210.9 million across 5 years, with a median of -$186.1 million in 2023.
- The sharpest annual moves came in 2023 and 2026: Income towards Parent Company sank 155.96% in 2023, then jumped 36.25% in 2026.
- A 5-year view of Income towards Parent Company shows it stood at -$160.1 million in 2022, then retreated by 16.23% to -$186.1 million in 2023, then fell by 26.61% to -$235.6 million in 2024, then slumped by 39.44% to -$328.5 million in 2025, then surged by 50.21% to -$163.6 million in 2026.
- The last three Income towards Parent Company figures came in at -$163.6 million (Q1 2026), -$328.5 million (Q4 2025), and -$370.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -163.56 Mn |
| Dec 31, 2025 | -328.49 Mn |
| Sep 30, 2025 | -370.00 Mn |
| Jun 30, 2025 | -321.69 Mn |
| Mar 31, 2025 | -256.57 Mn |
| Dec 31, 2024 | -235.58 Mn |
| Sep 30, 2024 | -220.51 Mn |
| Jun 30, 2024 | -300.61 Mn |
| Mar 31, 2024 | -157.09 Mn |
| Dec 31, 2023 | -186.06 Mn |
| Sep 30, 2023 | -158.93 Mn |
| Jun 30, 2023 | -244.81 Mn |
| Mar 31, 2023 | -159.76 Mn |
| Dec 31, 2022 | -160.08 Mn |
| Sep 30, 2022 | -131.17 Mn |
| Jun 30, 2022 | -95.65 Mn |
| Mar 31, 2022 | -94.62 Mn |
| Dec 31, 2021 | -112.94 Mn |
| Sep 30, 2021 | -112.71 Mn |
| Jun 30, 2021 | -117.30 Mn |